Abbott Biaxin XL
Executive Summary
"Some time in the third quarter, in advance of this year's flu season, we expect to hear from the FDA on our XL filing for community-acquired pneumonia," Abbott's Babington reports. Abbott filed for the new Biaxin XL indication in September 2000. The extended-release formulation of Abbott's macrolide antibiotic clarithromycin has "conversion tracking at more than 45% for the year"